Gilead Sciences, Inc. (GILD) - Financial and Strategic SWOT Analysis Review

Date: November 15, 2016
Pages: 69
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G8C59F02242EN
Leaflet:

Download PDF Leaflet

Gilead Sciences, Inc. (GILD) - Financial and Strategic SWOT Analysis Review
Gilead Sciences, Inc. (GILD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative medicines for diseases with unmet medical need. The company offers products in various therapeutic areas including cardiovascular, respiratory, inflammation, liver diseases, cancer and HIV/AIDS. Gilead operates through more than 40 marketing subsidiaries in the in Europe, North America, South America, Asia-Pacific, the Middle East, Africa and Australia. The company enters into partnerships with organizations in science, academia and business to develop innovative medicines. It continues to add to its existing portfolio of products through internal discovery and clinical development programs; and through a product acquisition and in-licensing strategy. Gilead is headquartered in Foster City, California, the US.

Gilead Sciences, Inc. Key Recent Developments

Nov 01, 2016: Gilead Sciences Announces Third Quarter 2016 Financial Results
Oct 24, 2016: Gilead Sciences announces encouraging data from two Phase III HIV-1 studies
Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers
Aug 23, 2016: Kelly A. Kramer Joins Gilead Sciences’ Board of Directors
Aug 11, 2016: ATF Urges Treasury and IRS to Act Against Gilead Science’s Massive Offshore Tax Dodging

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Gilead Sciences, Inc. - Key Facts
Gilead Sciences, Inc. - Key Employees
Gilead Sciences, Inc. - Key Employee Biographies
Gilead Sciences, Inc. - Major Products and Services
Gilead Sciences, Inc. - Pharmaceutical Pipeline Products Data
Gilead Sciences, Inc., Pipeline Products by Therapy Area
Gilead Sciences, Inc., Pipeline Products by Development Phase
Gilead Sciences, Inc. - History
Gilead Sciences, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Gilead Sciences, Inc. - Business Description
Gilead Sciences, Inc. - Corporate Strategy
Gilead Sciences, Inc. - SWOT Analysis
SWOT Analysis - Overview
Gilead Sciences, Inc. - Strengths
Gilead Sciences, Inc. - Weaknesses
Gilead Sciences, Inc. - Opportunities
Gilead Sciences, Inc. - Threats
Gilead Sciences, Inc. - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Gilead Sciences, Inc., Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Nov 01, 2016: Gilead Sciences Announces Third Quarter 2016 Financial Results
Oct 24, 2016: Gilead Sciences announces encouraging data from two Phase III HIV-1 studies
Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers
Aug 23, 2016: Kelly A. Kramer Joins Gilead Sciences’ Board of Directors
Aug 11, 2016: ATF Urges Treasury and IRS to Act Against Gilead Science’s Massive Offshore Tax Dodging
Aug 04, 2016: Tata Trusts and Gilead sign memorandum of understanding to address viral hepatitis in India
Jul 25, 2016: Gilead Sciences Announces Second Quarter 2016 Financial Results
May 24, 2016: Gilead Sciences Announces Appointment of Kevin Young CBE as Chief Operating Officer and Martin Silverstein, MD as Executive Vice President, Strategy
Apr 28, 2016: Gilead Sciences Announces First Quarter 2016 Financial Results
Mar 25, 2016: AHF: Gilead Says it “Had No Duty to Develop” Less Harmful AIDS Drug in Legal Motion on Patent Lawsuit

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer 69

LIST OF TABLES

Gilead Sciences, Inc., Key Facts
Gilead Sciences, Inc., Key Employees
Gilead Sciences, Inc., Key Employee Biographies
Gilead Sciences, Inc., Major Products and Services
Gilead Sciences, Inc., Number of Pipeline Products by Therapy Area
Gilead Sciences, Inc., Number of Pipeline Products by Development Stage
Gilead Sciences, Inc., Pipeline Products By Therapy Area and Development Phase
Gilead Sciences, Inc., History
Gilead Sciences, Inc., Other Locations
Gilead Sciences, Inc., Subsidiaries
Gilead Sciences, Inc., Joint Venture
Gilead Sciences, Inc., Key Competitors
Gilead Sciences, Inc., Ratios based on current share price
Gilead Sciences, Inc., Annual Ratios
Gilead Sciences, Inc., Interim Ratios
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Gilead Sciences, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios 68

LIST OF FIGURES

Gilead Sciences, Inc., Pipeline Products by Therapy Area
Gilead Sciences, Inc., Pipeline Products by Development Phase
Gilead Sciences, Inc., Performance Chart (2011 - 2015)
Gilead Sciences, Inc., Ratio Charts
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Skip to top


Ask Your Question

Gilead Sciences, Inc. (GILD) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: